608 Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors

Documenti analoghi

• Acute Interstitial Nephritis Triggered by a Novel Anti-CD25 Antibody-Drug Conjugate, Camidanlumab Tesirine
  di: Nicholas L. Li, et al.
  Pubblicazione: (2022-03-01)
• S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)
  di: C. Carlo-Stella, et al.
  Pubblicazione: (2022-06-01)
• In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine
  di: Paolo F. Caimi, et al.
  Pubblicazione: (2024-02-01)
• Vesiculobullous eruption with loncastuximab tesirine in a patient with relapsed follicular lymphoma
  di: Riyad N.H. Seervai, MD, PhD, et al.
  Pubblicazione: (2024-11-01)
• Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer
  di: Jonathan W. Goldman, et al.
  Pubblicazione: (2021-03-01)